<DOC>
	<DOC>NCT01464190</DOC>
	<brief_summary>This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.</brief_summary>
	<brief_title>A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Subjects who have completed treatment in Protocol PACL05A Written Informed Consent Hyper/hypo calcemia; hyper intact parathyroid hormone (iPTH) Other significant medical conditions Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>PA21</keyword>
	<keyword>Phosphate Binder</keyword>
</DOC>